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ORIGINAL ARTICLE
Regional brain metabolism in a murine systemic lupus
erythematosus model
An Vo1,4, Bruce T Volpe2,4, Chris C Tang1,4, Wynne K Schiffer1,4, Czeslawa Kowal2, Patricio T Huerta3, Aziz M Ulug˘1,
Stephen L Dewey1, David Eidelberg1,5 and Betty Diamond2,5
Systemic lupus erythematosus (SLE) is characterized by multiorgan inﬂammation, neuropsychiatric disorders (NPSLE), and anti-
nuclear antibodies. We previously identiﬁed a subset of anti-DNA antibodies (DNRAb) cross-reactive with the N-methyl-D-aspartate
receptor, present in 30% to 40% of patients, able to enhance excitatory post-synaptic potentials and trigger neuronal apoptosis.
DNRAbþ mice exhibit memory impairment or altered fear response, depending on whether the antibody penetrates the
hippocampus or amygdala. Here, we used 18F-ﬂuorodeoxyglucose (FDG) microPET to plot changes in brain metabolism after
regional blood–brain barrier (BBB) breach. In DNRAbþ mice, metabolism declined at the site of BBB breach in the ﬁrst 2 weeks and
increased over the next 2 weeks. In contrast, DNRAb mice exhibited metabolic increases in these regions over the 4 weeks after
the insult. Memory impairment was present in DNRAbþ animals with hippocampal BBB breach and altered fear conditioning in
DNRAbþ mice with amygdala BBB breach. In DNRAbþ mice, we observed an inverse relationship between neuron number and
regional metabolism, while a positive correlation was observed in DNRAb mice. These ﬁndings suggest that local metabolic
alterations in this model take place through different mechanisms with distinct time courses, with important implications for the
interpretation of imaging data in SLE subjects.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune disease
characterized by autoantibodies to nuclear antigens and systemic
inﬂammation. Anti-DNA antibodies are the most common
autoantibody, and cognitive and behavioral impairments are
common central nervous system (CNS) symptoms.1 Indeed, in the
past few decades investigators have come to realize both the
frequency and severity of the CNS manifestations of SLE in
patients and in mouse models. Because the symptoms of CNS
lupus are variable, and because brain tissue is rarely available
for analysis premortem, an understanding of pathogenetic
mechanisms of CNS manifestations of lupus, a major component
of neuropsychiatric lupus (NPSLE), has proven difﬁcult to achieve.
The pathophysiology for NPSLE in the CNS includes vascular and
parenchymal damage.2 Focal lesions result from inﬂammation or
thrombosis in the vessels, often mediated by anti-phospholipid
antibodies. The pathophysiology of diffuse CNS alterations is
complex and includes insults not only from anti-neuronal anti-
bodies, but probably also from cytokines and other inﬂammatory
mediators.1 Therefore, neuroimaging modalities have been
employed to identify physiologic changes associated with NPSLE.3
Functional brain imaging studies conducted in patients with SLE
have produced inconsistent ﬁndings. 18F-ﬂuorodeoxyglucose (FDG)
PET, which assays regional brain glucose utilization, has revealed
multifocal reductions in the frontal, parietal, and temporal gray
matter,4–9 changes thought to represent underlying cell injury,
neuronal death, or a combination of the two. However, the
observed metabolic changes seldom correlate with the localization
or severity of symptoms. More recent investigations have shown
increased glucose metabolism localized to the white matter,
consistent with the white matter loss in structural imaging
studies.7,10–13 Indeed, these changes have been thought to
reﬂect non-neuronal glucose metabolism and inﬂammation,12,14
and to precede the development of gray matter hypometabolism
secondary to deafferentation or neuronal loss, or both.
To understand the basis for these disparate ﬁndings, we have
developed an animal model with a deﬁned time of onset and
mechanism of brain injury. Because autoantibodies are a major
trigger for tissue injury in inﬂamed organs in SLE, we have focused
on brain-reactive antibodies. Anti-neuronal antibodies were
demonstrated in SLE patients many years ago, but a lack of
identiﬁcation of the antigenic target impeded mechanistic insight
into their potential pathogenicity. We demonstrated that a subset
of anti-DNA antibodies (DNRAb) also binds the N-methyl-D-
aspartate receptor (NMDAR).15,16 These antibodies can be
generated experimentally in mice.17,18 The antibodies preferen-
tially bind the active receptor and augment the effects of
glutamate, enhancing excitatory post-synaptic potentials, and
inducing excitotoxic neuron death at high concentrations.19
Treatment of DNRAbþ mice with an insult to the BBB in the
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hippocampus leads to an ensuing memory impairment,17 while
compromised BBB function in the amygdala leads to an alteration
in an associatively learned fear response.20 The initial lesion in
both situations is neuron loss within the region exposed to
DNRAbs without inﬁltration of blood–borne inﬂammatory cells
into the brain tissue. In this study, we used serial FDG-microPET to
deﬁne the regional distribution and time course of the alterations
in brain metabolism that result from lipopolysaccharide (LPS) or
epinephrine-induced exposure to DNRAbs. By assessing metabolic
activity at baseline, and twice more after the BBB insult, we found
comparable changes in metabolism that occurred in DNRAb
exposed regions. We also found metabolic changes that were
speciﬁcally related to local BBB breach, independent of DNRAb
exposure.
MATERIALS AND METHODS
Animals, Immunization Protocol, Enzyme-Linked Immunosorbent
Assay and Lipopolysaccharide or Epinephrine Treatment
Animals were handled according to the NIH Guide for the Care and Use of
Laboratory Animals and all procedures were approved by the IACUC at the
Feinstein Institute. Six- to eight-week-old BALB/c female mice from the
Jackson Laboratory (Bar Harbor, ME, USA) were used in all experiments.
The immunization protocols have been published.17 Brieﬂy, 20 mice were
immunized by intraperitoneal injection with 100mg of antigen, either MAP-
DWEYS (n¼ 10) or MAP-core (polylysine backbone) (n¼ 10) (AnaSpec, San
Jose, CA, USA) in complete Freund’s adjuvant followed by two boosts (2-
week intervals) in incomplete Freund’s adjuvant. Enzyme-linked immuno-
sorbent assays were performed after each immunization, as described
previously.18 Some immunized mice received an intraperitoneal
injection of LPS (Escherichia coli, 055:B5, Sigma, St Louis, MO, USA) at a
dose of 3mg/kg diluted in lactated Ringer’s solution to 0.3mg/ml.
Lipopolysaccharide treatments were given twice, 48 hours apart, at 4
weeks after the last immunization. Other mice received an intraperitoneal
injection of epinephrine (100 nmol/L in Ringer’s solution).20
Positron Emission Tomography Study in Mice
Animals received FDG (1.2–2.2mCi/kg) intraperitoneally and moved freely
in their home cage during the 45-minute uptake period, as described
elsewhere.21,22 Afterwards, animals were anesthetized with isoﬂurane,
placed into a stereotaxic frame, and moved into the gantry for imaging.
Animals were scanned at baseline (T1) before immunization with MAP-
DWEYS or control MAP-core on the Siemens Inveon (Siemens AG, Munich,
Germany) at the Feinstein Institute. They underwent repeat scanning at 2
(T2) and 4 weeks (T3) after LPS injection. For each scan, a single 10-minute
static emission scan was obtained, followed by an 8-minute attenuation
scan. Whole blood glucose values were collected in each scan and the
animals were returned to their home cage. All images were corrected for
attenuation and reconstructed using an iterative reconstruction approach
(maximum a priori (MAP) algorithms), as well as standard ﬁltered back
projection algorithms. Using PMOD software (PMOD Technologies, Zurich,
Switzerland), images were co-registered to a standard magnetic resonance
imaging mouse atlas.23 Serial metabolic data from DNRAbþ and
DNRAb mice were analyzed using statistical parametric mapping
mouse software (http://www.wbic.cam.ac.uk/Bsjs80/spmmouse.html),24
as described elsewhere.25,26 We ﬁrst speciﬁed a hypothesis-testing
mask, deﬁned by the difference between the ﬁrst (T1) and last (T3)
time point scans acquired in the DNRAb animals. The resulting
mask was thresholded at P¼ 0.001 at peak voxel, and corrected for
multiple comparisons at Po0.05 (false-positive discovery rate). Signiﬁcant
group time interaction effects on regional metabolism were sought
within this space using the baseline (T1) and ﬁnal (T3) scans from both
groups of animals. We performed additional statistical parametric mapping
analyses to evaluate group differences in the initial post -LPS time course
(i.e., between T1 and T2), and to identify interaction effects across all
three time points. For each analysis, clusters were considered signiﬁcant
for Po0.01 (uncorrected), with a cluster-size cutoff of 200 voxels. To
evaluate the time course of these effects, VOIs corresponding to signiﬁcant
regions were placed on the individual scans acquired at each time point.
For each VOI, longitudinal changes in globally normalized metabolic
activity were compared between groups using repeated measures analysis
of variance with post hoc Bonferroni tests. Results were considered
signiﬁcant for Po0.05.
Spatial Memory and Fear-Conditioning Task
Mice given LPS were assessed for spatial memory after the ﬁnal PET scan
was performed, at 8 weeks post-LPS administration. We used a navi-
gational test (clock maze task)16 that was modiﬁed from Deacon &
Rawlins.27 Mice given epinephrine were assessed for performance in a
fear-conditioning paradigm.20 Unmanipulated BALB/c mice were also
studied in each task (n¼ 10 for the spatial memory task; n¼ 9 for the fear-
conditioning task).
Brain Histology
Three mice in each group receiving LPS were killed after the third FDG-
micro PET scan and cognitive testing, and their brains were perfused with
heparinized saline followed by 4% paraformaldehyde, removed from the
skull, and frozen in OCT. Brains were then cut so that every third 20-mm
section through the dorsal anterior hippocampus and amygdala (bregma,
 2.0mm), the dorsal subiculum (bregma,  3.5mm), and the ventral
subiculum (bregma,  4.5mm) could be sampled with ﬁxed periodicity on
a Leica microtome (Buffalo Grove, IL, USA). Coronal sections were stained
with cresyl violet. Unbiased stereological neuron counts using cresyl violet
or neuron speciﬁc neu-N stain has yielded comparable data in our
database. Mosaic images of the regions of interest were compiled at  100
oil (ﬁxed total area¼ 0.044mm2) in Z-stack arrangements (1-mm steps;
Axio-Imager Z1, Zeiss, Thornwood, NY, USA). Images were analyzed using
unbiased stereological techniques (Stereologer, MBF, Williston, VT, USA). A
trained investigator (BTV), who was masked to the identity, experimental
status, and imaging ﬁndings of the individual animals conducted the
measurements. The coefﬁcient of error for the stereological measurements
across all the animals and all regions was, on average, 0.07 (n¼ 60). The
histologic coordinates for estimating neuron number in the ventral
subiculum were derived from the systematic sampling strategy and were
within the region of PET activation, as PET regions of interest coordinates
can be translated to standard atlas coordinates.23 The sample histologic
volume is B1/50th the volume of the PET activated regions of interest.
Statistical Analysis
Repeated measures analysis of variance (RMANOVA), followed by post hoc
Bonferroni tests, was used to examine the longitudinal changes in regional
metabolism in the hippocampus or amygdala between the DNRAbþ and
DNRAb mice after the injection of LPS or epinephrine. Analysis
of variance was also used to examine the changes in the performance in
a clock maze memory task, and t-test was used to examine the
performance in the tone and context fear conditioning. Nonparametric
Mann–Whitney U-test was used to compare the number of neurons in the
hippocampus between the DNRAbþ and DNRAb mice. Nonparametric
Spearman’s correlation coefﬁcient was calculated between the neuron
number in the ventral subiculum and the metabolism in the corresponding
regional cluster at 4 weeks post LPS for the DNRAbþ and DNRAb
animals. Statistical analyses were performed in SPSS 14.0 for Windows
(SPSS, Chicago, IL, USA) or OriginPro 9.1 (OriginLabs, Northampton, MA,
USA). Results were considered signiﬁcant for Po0.05.
RESULTS
In order to study the time course of behavioral, metabolic, and
histopathological changes after hippocampal exposure to
DNRAbs, mice were immunized with a peptide mimetope of
DNA multimerized on a polylysine backbone to generate DNRAbs
(DNRAbþ mice), or with the polylysine backbone alone
(DNRAb mice). Both mouse cohorts received LPS to breach
the BBB in the hippocampus,16,17,20 and underwent microPET at
three time points: 1 week before LPS injection, and 2 weeks and 4
weeks after LPS administration.
A whole brain voxel-wise search was conducted to identify
brain regions in which the time course of local metabolic activity
differed for DNRAbþ and DNRAb animals. This strictly data-
driven analysis revealed only a single region, the ventral
subiculum (Figure 1A) where a signiﬁcant difference was found
between the two groups of animals (P¼ 0.01; overall analysis
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three time points). The signiﬁcant interaction occurred in the ﬁrst
2 weeks (P¼ 0.01) but not in the subsequent 2 weeks (P¼ 0.52).
(Figure 1B).
No difference in the time course of global metabolic activity
after LPS was present between the two groups (P¼ 0.57). Globally
normalized metabolic activity in the ventral subiculum rose
steadily in the DNRAb animals over the 4 weeks that followed
LPS administration. In contrast, changes seen in the DNRAbþ
group after LPS administration had a signiﬁcantly different time
course (P¼ 0.01). These animals exhibited a decline in the
metabolic activity in this region between baseline and the 2-
week post-LPS time point, followed by an increase in metabolic
activity at 4 weeks post LPS. The proﬁle was consistent with a
biphasic process, in which the initial DNRAb-mediated insult in the
area of BBB breach led to a decreased metabolism presumably
secondary to neuronal loss, which we have previously shown
occurs in the ﬁrst week after antibody exposure.17 This ﬁrst phase
was followed by a phase of increasing metabolism that may
represent local glial cell inﬂammation, a compensatory neuronal
metabolic response, or a combination of the two.
After microPET, the LPS-treated mice were subjected to memory
assessment, with the investigator masked to the treatment group.
DNRAbþ mice (n¼ 9) were impaired compared to DNRAb
mice in spatial memory (P¼ 0.02) when tested in a clock maze at 8
weeks post LPS17 (Figure 1C). There was no detectable difference
between DNRAb mice and the unmanipulated BALB/c mice
(Figure 1C).
Histopathological analysis with unbiased stereology was
obtained in the dorsal CA1 and CA3 ﬁelds of the hippocampus,
ventral subiculum, posterior entorhinal cortex, and the lateral
anterior dorsal and superior basal lateral amygdala. DNRAbþ
mice (N¼ 3) displayed signiﬁcant reductions in the number of
neurons in the hippocampal regions previously shown to sustain
neuron loss (the CA1, and also in the CA3, ventral subiculum and
posterior entorhinal cortex) in comparison with DNRAb mice
(N¼ 3). Importantly, neuron number was also depressed in the
ventral subiculum, a region that overlapped with the microPET
data. Neuron number in the amygdala was comparable (P¼ 1)
(Figure 2A). Correlations between cell number in the ventral
subiculum and the metabolic activity in the corresponding
regional cluster at 4 weeks post LPS (Figure 2B) differed for
DNRAbþ and DNRAb animals. DNRAb mice exhibited a
signiﬁcant positive correlation between neuron number and
metabolic activity (Figure 2B, open circles), contrasting with a
negative correlation between neuron number and metabolic
activity in this region in DNRAbþ mice (Figure 2B, green).
These ﬁndings support the hypothesis that the hippocampal
metabolic reductions observed at 2 weeks post LPS in the
DNRAbþ mice were a reﬂection of recent local neuron loss. The
increases in metabolic activity that subsequently developed in
these animals may represent a compensatory response of the
surviving neurons in this brain region, a metabolic response in
non-neuronal cells, or a combination of the two effects. The
progressive metabolic increases in this region in DNRAb mice at
2 and 4 weeks after hippocampal breach may represent an acute
inﬂammatory response of glial cells to LPS exposure without the
cognitive impairment observed after hippocampal exposure to
DNRAbs.
To study the metabolic and behavioral changes after epinephr-
ine in the SLE animal model, mice were immunized as before, but
both DNRAbþ and DNRAb cohorts received epinephrine
(intrapertioneal 100 nmol/L epinephrine (Sigma)) in lactated
Ringer’s solution, as published, to breach the BBB in the amygdala,
and underwent microPET at three time points: 1 week before LPS
injection, and 2 weeks and 4 weeks after LPS administration.16,17,20
We determined if analogous DNRAb-mediated changes in
metabolism occurred in the amygdala after localized
epinephrine-induced BBB breach. Mice underwent FDG-PET 1
week before epinephrine administration and 2 and 4 weeks later.
There was no signiﬁcant difference in the course of global
Figure 1. Panel A shows a voxel-based comparison of 18F-fluorodeoxyglucose positron emission tomography images for mice carrying
DNRAbs and controls. The strictly data-driven comparison of mice carrying DRNAbs (DNRAbþ ) and control (DNRAb ) mice reveals a single
cluster in the ventral subiculum and entorhinal cortex (red) in which the metabolic changes significantly differ for the two groups over time.
The red cluster in panel A was obtained by a statistical parametric mapping interaction analysis of two groups two time points (0, 4 weeks)
(voxel-wise Pp0.01, kX220, cluster corrected Po0.05). The yellow cluster was obtained by a statistical parametric mapping interaction
analysis of two groups three time points (0, 2, 4 weeks) (voxel-wise Po0.005, k4500, cluster corrected Po0.05). The blue cluster was
obtained by a statistical parametric mapping comparison of 0 and 2 weeks for the DNRAbþ mice (voxel-wise Po0.001, k4640, cluster
corrected Po0.05). The significant clusters from these three analyses were located in the ventral subiculum and entorhinal hippocampus and
overlapped in this region. (B) Before LPS administration at baseline (0 weeks), resting metabolism in this region is equivalent in the DNRAb
(circles) and DNRAbþ (triangles) groups. The DNRAbþ mice show decreased regional metabolism 2 weeks after LPS administration that is
reversed by 4 weeks after LPS injection. In contrast, the DNRAb mice demonstrate continuously increasing regional metabolism from 0
weeks through 2 and 4 weeks. Of note, the rate of metabolic increase between 2 and 4 weeks was relatively faster in DNRAbþ mice (0.4/
week) than for DNRAb mice (0.2/week). There was a significant difference in the metabolic changes between the two groups over time
(group time interaction effect: F[2,36]¼ 4.8, P¼ 0.01; two-way repeated measures analysis of variance (RMANOVA) on the data at all three
time points). Further analyses revealed that this interaction effect occurred in the first 2 weeks after the injection (group time interaction
effect: F[1,18]¼ 6.73, P¼ 0.02; two-way RMANOVA on the data at baseline and 2 weeks ), but not over the subsequent 2 weeks (group time
interaction effect: F[1,18]¼ 0.44, P¼ 0.52; two-way RMANOVA on the data at 2 and 4 weeks). (C) DNRAbþ mice (n¼ 10) and DNRAb
controls (n¼ 10) were tested in the clock maze task 8 weeks post-LPS administration. DNRAbþ mice had impaired spatial memory
F[2,7]¼ 6.8, P¼ 0.02, analysis of variance). A cohort of unmanipulated BALB/c mice was also tested. There was no difference between this
cohort and the DNRAb mice.
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metabolism measured in the DNRAbþ and DNRAb groups over
time (P¼ 0.12). The DNRAb mice exhibited a continuous
increase in globally normalized metabolism in the amygdala
across the three time points. In contrast, DNRAbþ mice exhibited
a metabolic decline in the amygdala at 2 weeks (Figure 3A),
followed by increased activity in the same region at 4 weeks after
epinephrine (Pp0.001) (Figure 3B).
Behavior of both cohorts of mice was analyzed using a fear-
conditioning paradigm. DNRAbþ mice exhibited signiﬁcantly
decreased freezing scores compared to DNRAb mice in the tone
memory test (P¼ 0.007), as previously demonstrated20 (Figure 3C).
As with LPS-treated DNRAb mice, there was no impairment in
the epinephrine-treated DNRAb mice compared to unmanipu-
lated BALB/c mice (Figure 3C).
DISCUSSION
This study demonstrates localized increases in metabolic activity
in the hippocampus or amygdala after BBB disruption. Irrespective
of the insult mediating BBB disruption and the location of BBB
breach, DNRAbþ mice exhibited a pattern of metabolic change
that was not present in DNRAb mice; local metabolic activity
Figure 2. Panel A shows the number of neurons in the ventral subiculum in the DNRAbþ mice was decreased (Po0.005) 4 weeks after bloor–
brain barrier breach with lipopolysaccharide (LPS). This anatomic locus is comparable with the microPET loci. Neuron number in the
hippocampal CA1, CA3 and entorhinal region was decreased in DNRAbþ mice. Notably, the number of neurons in the amygdala (lateral
amygdala (LAd) and superior basolateral amygdala) was comparable. Neuron number was measured from both hemispheres of three animals
measured at 4 weeks for each group. Box-and-Whisker plots display the median and 25th and 75th percentiles of the neuron number of
animals in both groups. DNRAbþ mice had significant loss of neurons in the dorsal CA1 (Po0.0001), CA3 (Po0.008), ventral subiculum
(Po0.005), and posterior entorhinal cortex (Po0.005; Mann–Whitney). Neuron number in the amygdala was comparable (P¼ 1). (B) In
DNRAbþ mice (red), there was a significant inverse correlation (Po0.02) between the neuron number in the ventral subiculum and
metabolism, suggesting a compensatory response of the neurons or glial cells to the DRNAb-mediated insult. In contrast, the DNRAb mice
(black) demonstrate a positive correlation (Po0.02) between neuron number in the ventral subiculum and metabolism.
Figure 3. Panel A shows a voxel-based comparison of 18F-fluorodeoxyglucose positron emission tomography images for mice carrying
DNRAbs and controls. The strictly data-driven comparison of mice carrying DRNAbs (DNRAbþ ) and control (DNRAb ) mice reveals a single
cluster in the amygdala (red) in which the metabolic changes significantly differ for the two groups over time. The red cluster in panel A was
obtained by a statistical parametric mapping interaction analysis of two groups two time points (0, 4 weeks) (voxel-wise Po0.005, k4370,
cluster corrected Po0.05). (B) Before epinephrine administration at baseline (0 weeks), resting metabolism in this region is equivalent in the
DNRAb (circles) and DNRAbþ (triangles) groups. The DNRAbþ mice show decreased regional metabolism 2 weeks after epinephrine
administration that is reversed by 4 weeks after epinephrine injection. In contrast, the DNRAb mice demonstrate continuously increasing
regional metabolism from 0 weeks through 2 and 4 weeks. Of note, the rate of metabolic increase between 2 and 4 weeks was relatively faster
in DNRAbþ mice (0.4/week) than for DNRAb mice (0.2/week). There was a significant difference in the metabolic changes between the two
groups over time (group time interaction effect: F [2,36]¼ 9.59, Pp0.001; two-way repeated measures analysis of variance (RMANOVA) on
the data at all three time points). Furthermore, this interaction effect was present in the data at baseline and 2 weeks after the injection
(group time interaction effect: F[1,18]¼ 10.76, P¼ 0.005; two-way RMANOVA), but was absent between 2 and 4 weeks (group time
interaction effect: F[1,18]¼ 0.10, P¼ 0.75; two-way RMANOVA on the data at the last two time points). (C) Profile of freezing response.
DNRAbþ mice (n¼ 10) and DNRAb controls (n¼ 10) were tested in an associative learning fear paradigm 8 weeks post-epinephrine
administration. DNRAbþ mice had impaired associative learning of the fear response in the tone memory test (P¼ 0.0007, t-test). A cohort of
unmanipulated BALB/c mice was also tested and their behavior was not different from the behavior of DNRAb mice.
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was reduced relative to baseline at 2 weeks after BBB breach.
Obviously, LPS and epinephrine may have regional effects beyond
BBB breach, but the differential outcomes in the DNRAbþ and
DNRAb mice demonstrate the critical importance of barrier
breach. Thus, reduced metabolic activity was transient and,
therefore, would be unlikely to be detected as a consistent
change in cross-sectional human studies. Crucially, an unbiased
count of neurons within the hippocampal formation conﬁrmed
DNRAb-mediated neuron loss, consistent with our prior observa-
tion that neuronal death occurs in ﬁrst week after DNRAb
exposure.17 Moreover, the inverse correlation in DNRAbþ mice
between hippocampal cell counts and metabolic activity at
the 4-week time point suggests the gradual development of a
distinct and delayed tissue response. Blood–brain barrier integrity
has been shown to be restored soon after LPS administration.28
Our own data have demonstrated that no antibody is detectable
in the hippocampus within days of the BBB breach. Thus, the
increase in metabolism that occurs between 2 and 4 weeks after
LPS administration reﬂects either classic compensation with
metabolic increases that are ‘normalizing’ tissue activity, or a
non-neuronal inﬂammatory mechanism (for example, a glial
inﬂammatory response to neuronal necrosis) that raises
metabolic activity, albeit from the depressed levels seen at 2
weeks. It will be important to know whether the increase
continues beyond 4 weeks leading to greater than normal
hippocampal metabolism in DNRAbþ mice. Further, microglial
activity in DNRAbþ mice needs to be explored. By contrast, in
DNRAb animals, cell counts and metabolism in the
hippocampal formation exhibit a positive correlation consistent
with a localized inﬂammatory response of glial cells that does not
impair memory. Thus, normal FDG metabolism may be observed
in both healthy and damaged tissue, and similar metabolic proﬁles
may associate with distinct neurobehavioral outcome
assessments. This phenomenon of similar FDG-PET ﬁndings with
distinct etiologies and behavioral consequences was observed
also in the DNRAbþ mice with BBB breach in the amygdala.
Finally, a compensatory increase in the hippocampal activity
accords well with ﬁndings from functional magnetic resonance
imaging activation studies in SLE patients.29–32
In summary, the data presented suggest a model for some
NPSLE in which DNRAb-mediated cell loss in the hippocampus is
associated with a compensatory response in the surviving neurons
and subsequent increases in local glucose metabolism. However, a
localized response to other potential insults in SLE can similarly
result in abnormal metabolism in this region. Future studies
should determine whether these two pathologic entities can be
distinguished, and whether the increase in metabolism that
begins at 2 weeks after LPS in DNRAbþ mice continues such
that the mice eventually display increased hippocampal metabo-
lism. We propose a combination of 11C-PK11195 and 18F-FDG-PET
to measure microglial activation and regional metabolism to
provide a window into pathophysiology that neither tracer alone
can provide.
This study also demonstrates the need for caution in interpret-
ing PET data obtained from a single scan. The same pathophysiol-
ogy can be represented by different metabolic responses
depending upon the phase of the disease process at the time of
imaging.
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